tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

BTAI Stock Latest News

BioXcel Therapeutics announces results from PMR study of IGALMI
The FlyBioXcel Therapeutics announces results from PMR study of IGALMI
9d ago
BTAI
BioXcel Therapeutics Announces Positive Topline Results from Post-Marketing Requirement Study Evaluating PRN Treatment of IGALMI™ (dexmedetomidine) Sublingual Film for Agitation Associated with Bipolar Disorders or Schizophrenia
PremiumPress Releases
BioXcel Therapeutics Announces Positive Topline Results from Post-Marketing Requirement Study Evaluating PRN Treatment of IGALMI™ (dexmedetomidine) Sublingual Film for Agitation Associated with Bipolar Disorders or Schizophrenia
9d ago
BTAI
BioXcel Therapeutics to Present at Jefferies Global Healthcare Conference
PremiumPress Releases
BioXcel Therapeutics to Present at Jefferies Global Healthcare Conference
1M ago
BTAI
BioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
PremiumPress Releases
BioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
1M ago
BTAI
BioXcel Therapeutics reports Q1 EPS (87c), consensus (70c)
PremiumThe Fly
BioXcel Therapeutics reports Q1 EPS (87c), consensus (70c)
2M ago
BTAI
BioXcel Therapeutics Reports First Quarter 2024 Financial Results
PremiumPress ReleasesBioXcel Therapeutics Reports First Quarter 2024 Financial Results
2M ago
BTAI
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting
PremiumPress Releases
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting
2M ago
BTAI
Bioxcel Therapeutics Advances SERENITY Trial and Strategy
PremiumCompany Announcements
Bioxcel Therapeutics Advances SERENITY Trial and Strategy
2M ago
8K
BTAI
BioXcel announces plan for evaluating BXCL501 in at-home setting
PremiumThe Fly
BioXcel announces plan for evaluating BXCL501 in at-home setting
2M ago
BTAI
BioXcel Therapeutics price target lowered to $10 from $11 at H.C. Wainwright
PremiumThe Fly
BioXcel Therapeutics price target lowered to $10 from $11 at H.C. Wainwright
3M ago
BTAI
Bioxcel Therapeutics Advances Alzheimer’s Agitation Treatment Trial
PremiumCompany Announcements
Bioxcel Therapeutics Advances Alzheimer’s Agitation Treatment Trial
3M ago
8K
BTAI
BioXcel Therapeutics announces TRANQUILITY In-Care Phase 3 trial plan
PremiumThe Fly
BioXcel Therapeutics announces TRANQUILITY In-Care Phase 3 trial plan
3M ago
BTAI
BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s Dementia
PremiumPress ReleasesBioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s Dementia
3M ago
BTAI
BioXcel Therapeutics announces $25M registered direct offering
PremiumThe Fly
BioXcel Therapeutics announces $25M registered direct offering
3M ago
BTAI
BioXcel Therapeutics Announces $25 Million Registered Direct Offering
PremiumPress Releases
BioXcel Therapeutics Announces $25 Million Registered Direct Offering
3M ago
BTAI
Bioxcel Therapeutics Faces Market Estimation Risks Amidst Adoption and Access Challenges
PremiumCompany Announcements
Bioxcel Therapeutics Faces Market Estimation Risks Amidst Adoption and Access Challenges
3M ago
BTAI
Largest borrow rate increases among liquid names
PremiumThe Fly
Largest borrow rate increases among liquid names
4M ago
DNA
EVA
Largest borrow rate increases among liquid names
PremiumThe Fly
Largest borrow rate increases among liquid names
4M ago
CNQ
GFI
BioXcel Therapeutics announces European Patent Office grant
PremiumThe Fly
BioXcel Therapeutics announces European Patent Office grant
4M ago
BTAI
BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine
PremiumPress ReleasesBioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine
4M ago
BTAI
BioXcel Therapeutics price target lowered to $7 from $18 at Canaccord
PremiumThe Fly
BioXcel Therapeutics price target lowered to $7 from $18 at Canaccord
4M ago
BTAI
BioXcel Therapeutics price target lowered to $7 from $8 at BofA
PremiumThe Fly
BioXcel Therapeutics price target lowered to $7 from $8 at BofA
4M ago
BTAI

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >